| **Table 2. Comorbidities among Cancer Patients in the 2016-2018 NAMCS Study** | | | | | |
| --- | --- | --- | --- | --- | --- |
| Variable | Overall | No CANCER | CANCER | p | test |
| No. | 1744110764.3 | 1618816143.7 | 125294620.6 |  |  |
| HTN | 502994777.5 (28.8) | 449194466.7 (27.7) | 53800310.8 (42.9) | <0.001 |  |
| CKD | 57742902.3 (3.3) | 50929713.0 (3.1) | 6813189.3 (5.4) | 0.004 |  |
| COPD | 66723908.5 (3.8) | 58001274.3 (3.6) | 8722634.2 (7.0) | <0.001 |  |
| CHF | 34993972.1 (2.0) | 32851006.0 (2.0) | 2142966.1 (1.7) | 0.538 |  |
| CAD | 118674737.8 (6.8) | 105423636.8 (6.5) | 13251101.0 (10.6) | <0.001 |  |
| ESRD | 4348192.7 (0.2) | 3785177.1 (0.2) | 563015.6 (0.4) | 0.149 |  |
| HYPLIPID | 318364139.7 (18.3) | 287190118.9 (17.7) | 31174020.9 (24.9) | 0.002 |  |
| OBESITY | 139436310.6 (8.0) | 129263174.5 (8.0) | 10173136.1 (8.1) | 0.919 |  |
| OSA | 69633696.4 (4.0) | 62895932.9 (3.9) | 6737763.5 (5.4) | 0.030 |  |
| HPE | 0.0 (0.1) | 0.0 (0.1) | 0.0 (0.1) | 0.080 |  |
| CEBVD | 0.0 (0.1) | 0.0 (0.1) | 0.0 (0.2) | 0.017 |  |
| TOTCHRON | 1.1 (2.2) | 1.0 (2.2) | 2.7 (1.7) | <0.001 |  |
| DM2 | 211831499.0 (12.1) | 192235909.6 (11.9) | 19595589.4 (15.6) | 0.006 |  |
| Numbers are No. (%) unless otherwise noted.SD = standard deviation, IQR = interquartile range | | | | | |